Proton magnetic resonance spectroscopy of patients with parkinsonism

被引:78
作者
Abe, K
Terakawa, H
Takanashi, M
Watanabe, Y
Tanaka, H
Fujita, N
Hirabuki, N
Yanagihara, T
机构
[1] Osaka Univ, Grad Sch Med, Dept Neurol D4, Suita, Osaka 5650871, Japan
[2] Osaka Univ, Grad Sch Med, Dept Radiol, Suita, Osaka 5650871, Japan
关键词
proton magnetic resonance spectroscopy; H-1-MRS; N-acetylaspartate (NAA); parkinsonism; frontal lobe dysfunction;
D O I
10.1016/S0361-9230(00)00321-X
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
We studied cerebral metabolism in 82 patients with nonfamilial parkinsonism, including Parkinson's disease (PD; n = 23), progressive supranuclear palsy (PSP; n = 12), cortico-basal degeneration (CBD; n = 19), multiple systemic atrophy (MSA; n = 18) and vascular parkinsonism (VP; n = 10) by using proton magnetic resonance spectroscopy (H-1-MRS), which allowed noninvasive measurement of signal intensities from N-acetylasparate (NAA), choline-containing compounds (CHO) and creatine plus phosphocreatine (CRE). As compared to normal controls, patients with PSP, CBD, MSA and VP, but not PD, had significant reduction of the NAA/CRE ratio in the frontal cortex, whereas patients with PSP, CBD, MSA and PD, but not VP, had significant reduction of the NAA/CRE ratio in the putamen. Patients with CBD had significant reduction of the NAA/ CRE ratio in the frontal cortex and putamen as compared to patients with PD, MSA and VP. Patients with PSP showed a significant reduction of the NAA/CRE ratio in the putamen as compared with patients with PD and MSA. Patients with CBD showed clear asymmetry in the putamen as compared to controls and other patients. The reduction of the NAA/CRE ratio in the putamen correlated well with the severity of parkinsonism. H-1-MRS may be useful in monitoring patients with various types of parkinsonism. (C) 2000 Elsevier Science Inc.
引用
收藏
页码:589 / 595
页数:7
相关论文
共 62 条
  • [21] FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P18
  • [22] Diagnostic criteria for Parkinson disease
    Gelb, DJ
    Oliver, E
    Gilman, S
    [J]. ARCHIVES OF NEUROLOGY, 1999, 56 (01) : 33 - 39
  • [23] NEUROPATHOLOGY OF PARKINSONS-DISEASE AND RELATED SYNDROMES
    GIBB, WRG
    [J]. NEUROLOGIC CLINICS, 1992, 10 (02) : 361 - 376
  • [24] Gill S S, 1989, NMR Biomed, V2, P196, DOI 10.1002/nbm.1940020505
  • [25] CEREBRAL BLOOD-FLOW IN DEMENTIA
    HACHINSKI, VC
    ILIFF, LD
    ZILHKA, E
    DUBOULAY, GH
    MCALLISTER, VL
    MARSHALL, J
    RUSSELL, RWR
    SYMON, L
    [J]. ARCHIVES OF NEUROLOGY, 1975, 32 (09) : 632 - 637
  • [26] PRELIMINARY NINDS NEUROPATHOLOGIC CRITERIA FOR STEELE-RICHARDSON-OLSZEWSKI SYNDROME (PROGRESSIVE SUPRANUCLEAR PALSY)
    HAUW, JJ
    DANIEL, SE
    DICKSON, D
    HOROUPIAN, DS
    JELLINGER, K
    LANTOS, PL
    MCKEE, A
    TABATON, M
    LITVAN, I
    [J]. NEUROLOGY, 1994, 44 (11) : 2015 - 2019
  • [27] SPINOCEREBELLAR DEGENERATION (SCD) - COGNITIVE DISTURBANCES
    HIRONO, N
    YAMADORI, A
    KAMEYAMA, M
    MEZAKI, T
    ABE, K
    [J]. ACTA NEUROLOGICA SCANDINAVICA, 1991, 84 (03): : 226 - 230
  • [28] PARKINSONISM - ONSET PROGRESSION AND MORTALITY
    HOEHN, MM
    YAHR, MD
    [J]. NEUROLOGY, 1967, 17 (05) : 427 - &
  • [29] LOCALIZED PROTON NMR-SPECTROSCOPY IN THE STRIATUM OF PATIENTS WITH IDIOPATHIC PARKINSONS-DISEASE - A MULTICENTER PILOT-STUDY
    HOLSHOUSER, BA
    KOMU, M
    MOLLER, HE
    ZIJLMANS, J
    KOLEM, H
    HINSHAW, DB
    SONNINEN, P
    VERMATHEN, P
    HEERSCHAP, A
    MASUR, H
    RINNE, UK
    DEKOSTER, A
    TOSK, JM
    [J]. MAGNETIC RESONANCE IN MEDICINE, 1995, 33 (05) : 589 - 594
  • [30] Evidence for cortical dysfunction in clinically non-demented patients with Parkinson's disease: a proton MR spectroscopy study
    Hu, MTM
    Taylor-Robinson, SD
    Chaudhuri, KR
    Bell, JD
    Morris, RG
    Clough, C
    Brooks, DJ
    Turjanski, N
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1999, 67 (01) : 20 - 26